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Abstract
Introduction: Acute fatty liver of pregnancy (AFLP) is a rare but life-threatening disease. AFLP is characterized by
liver failure with different degrees of coagulopathy. Outcome and survival can be dramatically improved with
prompt recognition and treatment. Thromboelastometry has been considered a point of care for the management
of bleeding patients. It could, therefore, be an alternative tool to treat the complex cases of AFLP involving liver
failure and coagulopathy. Through this study, we present our successful experience of an AFLP case that was
submitted to an emergency cesarean section in which blood transfusion was guided by thromboelastometry.
Case presentation: We report the case of a previously healthy 28-year-old woman, Afro-Brazilian, in her first
pregnancy with no medical records until the 36th pregnancy week. She presented to our emergency department
with an acute onset of abdominal pain, jaundice, nausea and vomiting. The laboratory examinations revealed
metabolic acidosis, acute kidney injury (serum creatinine 3.4mg/dL), platelets 97 × 103/mm3, serum fibrinogen
98mg/dL and increased international nationalized ratio (INR 6.9) without acute bleeding. An emergency cesarean
section was indicated. Based on the results of the thromboelastometric tests EXTEM and FIBTEM, prothrombin
complex concentrate and fibrinogen concentrate were administered at the beginning of the cesarean section,
which succeeded with no major bleeding and without need of further transfusion.
Conclusions: Thromboelastometry may be considered a useful, feasible and safe tool to monitor and manage
coagulopathy in obstetric patients with acute fatty liver of pregnancy, with the potential advantage of helping
avoid unnecessary transfusion in such patients.
Introduction
Acute fatty liver of pregnancy (AFLP) represents a rare
but potentially fatal pregnancy complication, usually di-
agnosed during the last trimester or early in the postpar-
tum period [1]. The clinical picture of AFLP is
nonspecific and comprises headache, fatigue, anorexia,
nausea, vomiting, abdominal pain, fever and jaundice
[1]. However, the most severe spectrum of the AFLP is
characterized by an early multiorgan involvement [1].
Liver failure is the landmark of the AFLP and may be ac-
companied by encephalopathy, gastrointestinal bleeding,
acute kidney injury and different degrees of coagulopa-
thy, which intensify the risk of obstetric hemorrhage and
death [2].
The histopathological characteristic of AFLP is dis-
seminated microvesicular fatty infiltration of hepatocytes
with minimal cholestasis without necrosis [3]. The AFLP
affects 1 in 7,000 to 13,000 pregnancies [3]. Maternal
mortality rate has been estimated to be as high as 18%,
and the neonatal mortality rate can range from 7% up to
58% [4]. The pathophysiology of AFLP is not completely
understood but this condition has been associated with
an inherited deficiency of the mitochondrial enzyme
long-chain 3-hydroxyacetyl-coenzyme-A dehydrogenase
(LCHAD) [1].
It has been postulated that HELLP syndrome
(hemolysis, elevated liver enzymes and low platelets),
preeclampsia, thrombotic thrombocytopenic purpura
and AFLP may all be a spectrum of the same disease
[4, 5]. Therefore, its early diagnosis represents a chal-
lenge for the clinicians at the bedside [4]. Most
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patients will recover within 4 weeks after the delivery [6].
Nevertheless, it is important to emphasize that outcomes
and survival can be dramatically improved with timely
recognition and prompt treatment [6].
Thromboelastometry represents a viscoelastic test that
has been considered an important tool for the manage-
ment of critically ill patients [7]. It has been used mainly
for early prediction of bleeding complications and goal-
directed therapy in different scenarios, such as trauma,
septic shock, anesthesia, hepatic and cardiac surgeries
[8]. It is well known that standard plasmatic coagulation
screening tests such as activated partial thromboplastin
time (aPTT) or prothrombin time (PT) represent weak
predictors of bleeding in critically ill patients; they repre-
sent suboptimal tests for monitoring coagulopathy and
guide hemostatic therapy [7].
Therefore, thromboelastometry-guided hemostatic ther-
apy could be considered an alternative tool to manage
complex cases of AFLP that are characterized by liver fail-
ure and coagulopathy. We are not aware of any report ad-
dressing the thromboelastometry role to monitor the
coagulation system and guide hemostatic therapy in AFLP
patients. Consequently, our objective was to describe a
case of an acute fatty liver of a pregnant patient in which
thromboelastometry was successfully used to identify co-
agulopathy and guide transfusion.
Case presentation
We report the case of a previously healthy 28-year-old
woman, Afro-Brazilian, in her first pregnancy. Our pa-
tient had no medical records until the 36th pregnancy
week and reported allergy to diclofenac. She presented
to our emergency department with an acute onset of ab-
dominal pain, jaundice, nausea and vomiting, with no
signs of encephalopathy. Her arterial blood pressure was
110/60mmHg, heart rate was 98bpm, axillary temperature
was 35°C, she was severely dehydrated and with decreased
peripheral perfusion.
The laboratory examinations revealed hemoglobin
12.3g/dL, leukocytes 13 × 109/mL, platelets 97 × 103/mm3,
international nationalized ratio (INR) 6.9, fibrinogen
98mg/dL, total bilirubin 14.2mg/dL, serum creatinine
3.4mg/dL, serum aspartate aminotransferase (AST) 306U/
L, serum alanine aminotransferase (ALP) 302U/L, arterial
bicarbonate 11mEq/L, arterial pH 7.21, blood glucose
65mg/dL and ionic calcium 1.02mmol/L. An abdominal
ultrasound depicted fatty infiltration of the liver and con-
firmed fetal viability.
Our patient received an initial fluid load with crystal-
loids. The calcium, glucose and hypothermia were re-
versed. The diagnosis of AFLP was confirmed following
the Swansea’s criteria [9]. Therefore, a cesarean section
was indicated. A thromboelastometry (ROTEM®, Penta-
pharm Co., Munich, Germany) was performed at the
beginning of the surgery. The thromboelastometry ana-
lysis showed an intense kinetic and structural hypocoa-
gulable state (Fig. 1 and Table 1). The FIBTEM revealed
an impairment in fibrinogen function quality while the
EXTEM depicted a coagulation factor deficiency (Fig. 1a-c
and Table 1).
Based on, respectively, FIBTEM maximum clot firm-
ness (MCF) (0mm; Table 1) and EXTEM clotting time
(CT) (228s; Table 1), 4.0g of fibrinogen concentrate
(Haemocomplettan® P, CSL Behring, Marburg, Germany)
and 1000UI of prothrombin complex concentrate (Beri-
plex® P/N 500UI, CSL Behring, Marburg, Germany) were
administered at the beginning of the cesarean section.
The fluid input (crystalloids) and output during the cae-
sarian section were, respectively, 2000mL and 200mL.
The cesarean section succeeded with no major bleeding
after the hemostatic therapy.
Additional hemocomponent transfusion, such as fresh
frozen plasma (FFP), cryoprecipitate, platelets or blood
concentrates, was not necessary. A second thromboelas-
tometry analysis was performed at the end of surgery
(Fig. 1d-e and Table 1), showing a mild hypocoagulation
state. The patient was admitted to the intensive care unit
(ICU) and remained stable, with no bleeding during the
recovery phase. She was discharged from the ICU 3 days
after admission and then 3 days later she was discharged
from the hospital.
Discussion
Acute fatty liver of pregnancy occurs suddenly during
the last trimester, when fatty infiltration of hepatocytes
will cause hepatic failure and consequently encephalop-
athy and different degrees of coagulopathy [5]. Although
its exact pathogenesis is not completely known, this dis-
ease has been associated with an abnormality in fetal
fatty acid metabolism [3]. AFLP can lead to significant
maternal and fetal morbidity and mortality. In the past,
this condition was practically fatal. However, nowadays it
is possible to stabilize the condition of the mother with
safety through the available intensive care resources.
The diagnosis of AFLP is still a challenging task for
clinicians because of its nonspecific clinical presentation,
which may be mistaken with other diseases as such
HELLP syndrome, acute viral hepatitis and preeclampsia
[5]. The clinical findings of AFLP are characterized by
varying degrees of severity along with the classical symp-
toms of the third pregnancy trimester, making early
diagnosis difficult [2]. Patients usually show nonspecific
symptoms such as anorexia, nausea, vomiting, malaise,
fatigue, headache and abdominal pain [2]. In the most
severe cases, patients may have dysfunctions of add-
itional systems, including acute renal failure, hepatic en-
cephalopathy, pancreatitis, gastrointestinal bleeding and
coagulopathy [10].
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Laboratory abnormalities detected with conventional
coagulation tests such as aPTT, PT, fibrinogen and platelet
count can be prophylactically corrected with replacement
of FFP, cryoprecipitate, packed red cells or platelet con-
centrates [11]. Nevertheless, the current literature sug-
gests that prophylactic transfusion of blood products
aiming to correct laboratory abnormalities increases the
risk of acute lung injury, fluid overload, infection, im-
munosuppression, organ dysfunction and, therefore,
should not be performed [12]. Furthermore, it is well
known that the standard plasmatic coagulation screening
tests represent weak predictors of bleeding in the critically
ill patients and represent suboptimal tests for monitoring
coagulopathy or guiding hemostatic therapy [13].
The principle of thrombelastography was described in
1948. Thrombelastography is a method, unlike the
conventional or standard coagulation tests, which is able
to monitor the whole-blood coagulation system and
Fig. 1 Thromboelastometry analysis (ROTEM®) at the beginning of the cesarean section. a-c Thromboelastometry analysis (ROTEM®) performed at
the beginning of the cesarean section (time 0) showing an intense kinetic and structural hypocoagulable state. a EXTEM showing a coagulation
factor deficiency. c FIBTEM showing an impairment in fibrinogen function quality. d-f Second thromboelastometry analysis performed after 4.0g
of fibrinogen concentrate (Haemocomplettan® P, CSL Behring, Marburg, Germany) and 1000UI of prothrombin complex concentrate (Beriplex®
P/N 500UI, CSL Behring, Marburg, Germany) administration (time 3 hours)
Crochemore et al. Journal of Medical Case Reports  (2015) 9:202 Page 3 of 5
determine the clot strength as well as the lytic processes
[14]. By providing a graphic presentation of the fibrin
polymerization and lysis, thrombelastography reflects the
viscoelastic changes that occur during the coagulation
process [14]. Although thrombelastography provides in-
teresting analytical information from the very beginning
of clot formation, it was seldom used in routine clinical
practice because of its extreme sensitivity to vibration and
mechanical shock.
However, at the beginning of the 1990s, the principle
of thromboelastometry (ROTEM®) was developed. In
contrast to the classical thrombelastography, thromboe-
lastometry is practically insensitive to environmental ar-
tefacts and it is easy to handle. In contrast to the
original method, automated pipetting in ROTEM allows
complex coagulation analyses to be performed.
As pointed out before, thromboelastometry represents
a viscoelastic test that has been considered an important
tool for the management of critically ill patients [7].
Thromboelastometry enables a contemporary detection
of several hemostatic disorders within 5 minutes (ampli-
tude at 5 minutes) after CT EXTEM, INTEM and FIB-
TEM in patients with severe coagulopathy [15, 16]. It
has been used mainly for early prediction of bleeding
complications and goal-oriented therapy with specific
hemostatic drugs such as coagulation factor concentrates
and blood products in different patients, including
trauma, sepsis, anesthesia, liver and cardiac surgeries.
The ROTEM® allows four independent measuring
channels and assays. Several activators and additives are
commercially available nowadays (EXTEM, INTEM,
FIBTEM, HEPTEM and APTEM) and are used to detect
specific hemostatic defects such as coagulation factor
deficiencies, thrombocytopenia, heparin and protamine
effects, hypofibrinogenemia, hyperfibrinolysis and finally,
fibrin polymerization disorders.
For the interpretation of thromboelastometric assays,
the following variables should be analyzed together: CT,
clot formation time (CFT) and MCF. Clotting time rep-
resents the time from adding the start reagent to the
citrated blood sample until the clot starts to form (clot
firmness of 2mm). Prolongation of the CT may be the
result of coagulation factor deficiencies or the effect of
anticoagulants such as heparin. Furthermore, it has been
demonstrated that CT prolongation may also occur
when not enough fibrinogen is available for clot formation
[17–19]. Therefore, a stepwise approach for hemostatic
therapy is advisable. When CT is prolonged, fibrinogen
should be replaced first and then, if CT remains pro-
longed, coagulation factor deficiency should be cor-
rected with FFP or prothrombin complex concentrate
administration.
An abnormal clot formation is indicated by a prolonged
clot formation time (period from 2mm to 20mm of ampli-
tude) and/or a reduced maximum clot firmness. The max-
imum clot firmness represents the greatest amplitude of
the thromboelastometric trace and reflects the “strength”
of the clot. A low MCF is indicative of decreased platelet
concentration and/or function, decreased fibrinogen con-
centration and/or fibrin polymerization disorders, or low
activity of factor XIII. A mechanically weak clot represents
a severe bleeding risk. Fibrinolysis is detected by the lysis
of the clot [maximum lysis (ML) > 15%].
The initial results of conventional coagulation tests of the
previously presented case revealed a low platelet count and
fibrinogen and an increased INR. Based on these results,
our patient should have received FFP, platelets and cryopre-
cipitate to avoid peri-operative bleeding. Nevertheless, the
ROTEM® depicted a severe kinetic and structural hypocoa-
gulable state secondary to hypofibrinogenemia and coagula-
tion factor deficiency. These results led us to an early
identification of structural coagulopathy and the underlying
coagulation disorder. By administering fibrinogen concen-
trates and prothrombin complex, it was possible to correct
the coagulation disorder avoiding intraoperative bleeding.
More importantly, with no need of blood products
administration.
It is important to emphasize that conventional coagu-
lation tests do not allow us to address the underlying co-
agulation disorder, often resulting in a replacement of
blood components unnecessarily [12]. The thromboelasto-
metry analysis allows clinicians to recognize the presence
of coagulopathy and, most importantly, to understand the
underlying clotting disorder. Early ROTEM-guided trans-
fusion in the case presented avoided unnecessary blood
transfusions, minimizing the risk of serious transfusion-
related complications, such as acute lung injury (TRALI),
Table 1 Sequential thromboelastometry (ROTEM®) analysis from
the emergency department admission through intensive care
unit discharge
Time (hours) Assays CT (s) CFT (s) α angle (°) MCF (mm) LI60 (%)
0 EXTEM 228 1168 22 29 100
INTEM 614 1792 16 27 100
FIBTEM - - - 0 -
3 EXTEM 109 328 50 43 100
INTEM 213 302 50 43 100
FIBTEM - - - 3 -
24 EXTEM 70 318 43 44 100
INTEM 265 265 50 44 100
FIBTEM - - - 5 -
36 EXTEM 62 282 58 42 100
INTEM 224 228 57 43 100
FIBTEM - - - 10 -
CT clotting time, CFT clot formation time, MCF maximum clot firmness, LI60
lysis index 60
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transfusion acute cardiac overload (TACO) and risk of in-
fections [20].
Our patient had a serious case of hypofibrinogenemia
and deficiency of coagulation factors. Observational stud-
ies have been suggesting an association between low fi-
brinogen levels and the risk and severity of postpartum
hemorrhage [21]. Therefore, the increased bleeding risk in
this population of patients might overcome the potential
risk of adverse reactions associated with fibrinogen con-
centrate administration. More importantly, it was possible
to correct the hypofibrinogenemia by replacing 4.0g of fi-
brinogen concentrate. Had we used conventional tests to
guide blood transfusion therapy, we would have used FFP
and cryoprecipitate instead of fibrinogen concentrate and
prothrombin complex concentrate, thereby increasing the
risk of blood-related adverse events. Additionally, it is well
known that FFP contains low amounts of fibrinogen, ap-
proximately 250mg per unit. Therefore, 16 units of FFP
would be necessary to replace the same 4.0g of fibrinogen
administered with fibrinogen concentrate.
Conclusions
In summary, successful management of patients with AFLP
is a challenge. Both outcome and survival rate can be im-
proved with prompt recognition and early treatment.
Thromboelastometry may be considered a useful, feasible
and safe tool to monitor and manage coagulopathy in obstet-
ric patients with AFLP. Nevertheless, additional studies are
needed to define the actual benefit of thromboelastometry
for early coagulopathy identification, bleeding predictor, and
finally as a guide for blood products and hemostatic drugs.
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